|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000043039 |
Summary for BARX2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000043039 | Gene symbol | BARX2 |
| Gene name | BARX homeobox 2 | |
| HGNC | 956 | |
| Entrez ID | 8538 | |
| Gene type | protein_coding | |
| Synonyms | BARX2| | |
| UniProtAcc | Q9UMQ3 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for BARX2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| BARX2 | 1.20e+03 | -2.10e+00 | 3.77e-01 | -5.57e+00 | 2.62e-08 | 2.15e-07 | STAD |
| BARX2 | 1.70e+03 | 2.03e+00 | 6.04e-01 | 3.36e+00 | 7.70e-04 | 5.12e-03 | ESCA |
| BARX2 | 4.04e+02 | 6.06e+00 | 1.05e+00 | 5.77e+00 | 7.71e-09 | 8.96e-08 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| BARX2 | 1.09e+03 | 1.26e+00 | 3.99e-01 | 3.16e+00 | 1.60e-03 | 3.38e-03 | KICH |
| BARX2 | 2.13e+02 | -1.71e+00 | 6.07e-01 | -2.82e+00 | 4.76e-03 | 1.32e-02 | READ |
Top |
Sex-biased somatic mutation for BARX2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for BARX2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LIHC | cg07355688 | chr11:129376823 | CGI:chr11:129372634-129376500 | promoter,gene body | 3.76e-01 | 2.44e-01 | 4.78e+00 | 1.72e-06 | 2.28e-05 | 1.32e-01 |
| ESCA | cg04299135 | chr11:129374546 | CGI:chr11:129372634-129376500 | promoter | 1.57e-01 | 5.02e-02 | 3.12e+00 | 1.80e-03 | 7.51e-03 | 1.06e-01 |
| ESCA | cg04094148 | chr11:129374628 | CGI:chr11:129372634-129376500 | promoter | 2.05e-01 | 7.08e-02 | 3.36e+00 | 7.75e-04 | 3.58e-03 | 1.34e-01 |
| ESCA | cg17692125 | chr11:129374610 | CGI:chr11:129372634-129376500 | promoter | 1.99e-01 | 5.48e-02 | 3.27e+00 | 1.07e-03 | 4.80e-03 | 1.45e-01 |
| CHOL | cg21697198 | chr11:129376499 | CGI:chr11:129372634-129376500 | promoter,gene body | 3.39e-01 | 2.03e-01 | 2.10e+00 | 3.56e-02 | 4.34e-02 | 1.36e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| HNSC | cg04094148 | chr11:129374628 | CGI:chr11:129372634-129376500 | promoter | 1.67e-01 | 4.29e-02 | 3.97e+00 | 7.23e-05 | 1.97e-04 | 1.24e-01 |
| HNSC | cg17692125 | chr11:129374610 | CGI:chr11:129372634-129376500 | promoter | 1.41e-01 | 3.15e-02 | 3.30e+00 | 9.75e-04 | 1.77e-03 | 1.09e-01 |
| LUSC | cg04299135 | chr11:129374546 | CGI:chr11:129372634-129376500 | promoter | 2.37e-01 | 4.14e-02 | 2.94e+00 | 3.29e-03 | 5.99e-03 | 1.96e-01 |
| LUSC | cg04094148 | chr11:129374628 | CGI:chr11:129372634-129376500 | promoter | 2.97e-01 | 8.23e-02 | 2.44e+00 | 1.49e-02 | 1.89e-02 | 2.15e-01 |
| LUSC | cg17692125 | chr11:129374610 | CGI:chr11:129372634-129376500 | promoter | 2.84e-01 | 5.37e-02 | 2.24e+00 | 2.53e-02 | 2.88e-02 | 2.31e-01 |
| LUSC | cg21697198 | chr11:129376499 | CGI:chr11:129372634-129376500 | promoter,gene body | 1.65e-01 | 5.85e-02 | 2.73e+00 | 6.39e-03 | 9.82e-03 | 1.07e-01 |
| BLCA | cg07355688 | chr11:129376823 | CGI:chr11:129372634-129376500 | promoter,gene body | 1.84e-01 | 3.29e-01 | -3.92e+00 | 8.96e-05 | 3.70e-04 | -1.45e-01 |
| LIHC | cg07355688 | chr11:129376823 | CGI:chr11:129372634-129376500 | promoter,gene body | 2.44e-01 | 3.48e-01 | -4.12e+00 | 3.77e-05 | 8.73e-05 | -1.04e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg04299135 | chr11:129374546 | CGI:chr11:129372634-129376500 | promoter | 1.84e-01 | 4.47e-02 | 6.76e+00 | 1.38e-11 | 3.89e-11 | 1.40e-01 |
| BRCA | cg04094148 | chr11:129374628 | CGI:chr11:129372634-129376500 | promoter | 2.33e-01 | 5.76e-02 | 7.10e+00 | 1.22e-12 | 3.73e-12 | 1.76e-01 |
| BRCA | cg17692125 | chr11:129374610 | CGI:chr11:129372634-129376500 | promoter | 2.16e-01 | 3.89e-02 | 6.22e+00 | 4.96e-10 | 1.24e-09 | 1.77e-01 |
| BRCA | cg07355688 | chr11:129376823 | CGI:chr11:129372634-129376500 | promoter,gene body | 2.19e-01 | 3.89e-01 | -1.28e+01 | 1.87e-37 | 8.45e-36 | -1.70e-01 |
| LIHC | cg04094148 | chr11:129374628 | CGI:chr11:129372634-129376500 | promoter | 2.08e-01 | 7.68e-02 | 2.07e+00 | 3.84e-02 | 4.05e-02 | 1.32e-01 |
| LIHC | cg17692125 | chr11:129374610 | CGI:chr11:129372634-129376500 | promoter | 2.09e-01 | 4.88e-02 | 3.13e+00 | 1.75e-03 | 3.50e-03 | 1.60e-01 |
| LIHC | cg21697198 | chr11:129376499 | CGI:chr11:129372634-129376500 | promoter,gene body | 2.86e-01 | 1.36e-01 | 2.77e+00 | 5.67e-03 | 8.86e-03 | 1.50e-01 |
Top |
Exon skipping events with PSI in TCGA for BARX2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for BARX2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for BARX2 |
| TFs related to BARX2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BARX2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
 |
Top |
Sex-biased RBP-ES network for BARX2 |
| RBPs related to ES in BARX2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BARX2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000043039 | AC144831.1,hsa-mir-372,BARX2 | Tumor-specific sex-biased ceRNA | TCGA-LIHC |
| ENSG00000043039 | AC092756.1,hsa-mir-373,BARX2 | Male-specific ceRNA | TCGA-LIHC |
| ENSG00000043039 | AC087477.2,hsa-mir-373,BARX2 | Male-specific ceRNA | TCGA-LIHC |
| ENSG00000043039 | AC015712.2,hsa-mir-373,BARX2 | Male-specific ceRNA | TCGA-LIHC |
| ENSG00000043039 | AL136982.6,hsa-mir-373,BARX2 | Male-specific ceRNA | TCGA-STAD |
| ENSG00000043039 | LINC01395,hsa-mir-373,BARX2 | Male-specific ceRNA | TCGA-STAD |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs7125158 | chr11:120650596:A:C | - | 0.214771281385133 | 0.0171139770607079 | KIRP | Female-baised eQTL |
| rs329654 | chr11:133982713:C:T | - | -0.143305121492215 | 0.00494101430643953 | LUSC | Female-baised eQTL |
| rs329662 | chr11:133976009:T:A | - | -0.153053140336477 | 0.00512254894929006 | LUSC | Female-baised eQTL |
| rs329658 | chr11:133979386:T:C | - | -0.153053140336477 | 0.00512254894929006 | LUSC | Female-baised eQTL |
| rs329660 | chr11:133976604:A:G | - | -0.152820025149918 | 0.00521857092937153 | LUSC | Female-baised eQTL |
| rs329657 | chr11:133979508:G:A | - | -0.146923182554893 | 0.00772154997795892 | LUSC | Female-baised eQTL |
| rs329680 | chr11:133972585:T:C | - | -0.118747304364507 | 0.0354870109358729 | LUSC | Female-baised eQTL |
| rs3758770 | chr11:128802931:C:T | - | 0.0507639701349021 | 0.000434374506994705 | LUAD | Female-baised eQTL |
| rs2268611 | chr11:128798197:T:C | - | 0.0494120052581768 | 0.000650570428800439 | LUAD | Female-baised eQTL |
| rs59460980 | chr11:128799279:C:T | - | 0.049343802694487 | 0.000668458663360939 | LUAD | Female-baised eQTL |
| rs2284788 | chr11:128800220:C:T | - | 0.049343802694487 | 0.000668458663360939 | LUAD | Female-baised eQTL |
| rs2268608 | chr11:128797752:G:C | - | 0.0405009309222847 | 0.00567290667414236 | LUAD | Female-baised eQTL |
| rs2268598 | chr11:128794370:T:C | - | 0.039344612852186 | 0.00874329036146741 | LUAD | Female-baised eQTL |
| rs34591296 | chr11:123679762:G:A | - | 0.0415346544676487 | 0.00902039631294418 | LUAD | Female-baised eQTL |
| rs2071617 | chr11:128806973:G:T | - | 0.037715876950833 | 0.010246052139595 | LUAD | Female-baised eQTL |
| rs2071618 | chr11:128807018:A:G | - | 0.037715876950833 | 0.010246052139595 | LUAD | Female-baised eQTL |
| rs2071619 | chr11:128807564:C:T | - | 0.037715876950833 | 0.010246052139595 | LUAD | Female-baised eQTL |
| rs12421884 | chr11:128802289:G:A | - | 0.0369970363298593 | 0.0132688296800904 | LUAD | Female-baised eQTL |
| rs3758768 | chr11:128803284:A:C | - | 0.0364334158255801 | 0.0138185594472319 | LUAD | Female-baised eQTL |
| rs12417018 | chr11:128803340:G:A | - | 0.0366408773071531 | 0.0138775309335432 | LUAD | Female-baised eQTL |
| rs3781722 | chr11:128796701:G:A | - | 0.0374476258454593 | 0.0143325899687683 | LUAD | Female-baised eQTL |
| rs3824899 | chr11:128797133:G:A | - | 0.0374016159844788 | 0.0146258798087329 | LUAD | Female-baised eQTL |
| rs2268606 | chr11:128797501:A:C | - | 0.0374016159844788 | 0.0146258798087329 | LUAD | Female-baised eQTL |
| rs2268609 | chr11:128798053:G:C | - | 0.0373624661551773 | 0.0148799468063065 | LUAD | Female-baised eQTL |
| rs2268610 | chr11:128798105:A:G | - | 0.0373624661551773 | 0.0148799468063065 | LUAD | Female-baised eQTL |
| rs56075660 | chr11:128794112:A:G | - | 0.0361396724569986 | 0.0164518455934233 | LUAD | Female-baised eQTL |
| rs3781721 | chr11:128796852:A:G | - | 0.0366119968392004 | 0.017679739748174 | LUAD | Female-baised eQTL |
| rs2300594 | chr11:128793068:G:A | - | 0.0359051669142757 | 0.017683462782613 | LUAD | Female-baised eQTL |
| rs61909388 | chr11:128793356:G:A | - | 0.0359051669142757 | 0.017683462782613 | LUAD | Female-baised eQTL |
| rs61909389 | chr11:128793686:G:T | - | 0.0359051669142757 | 0.017683462782613 | LUAD | Female-baised eQTL |
| rs56259986 | chr11:128793930:G:T | - | 0.0359051669142757 | 0.017683462782613 | LUAD | Female-baised eQTL |
| rs56275929 | chr11:128794133:C:T | - | 0.0359051669142757 | 0.017683462782613 | LUAD | Female-baised eQTL |
| rs56275778 | chr11:128794200:A:G | - | 0.0359051669142757 | 0.017683462782613 | LUAD | Female-baised eQTL |
| rs2268597 | chr11:128794282:T:C | - | 0.0359051669142757 | 0.017683462782613 | LUAD | Female-baised eQTL |
| rs2268600 | chr11:128794695:C:T | - | 0.0359051669142757 | 0.017683462782613 | LUAD | Female-baised eQTL |
| rs2268601 | chr11:128794846:T:C | - | 0.0359051669142757 | 0.017683462782613 | LUAD | Female-baised eQTL |
| rs2268604 | chr11:128796210:C:A | - | 0.0359051669142757 | 0.017683462782613 | LUAD | Female-baised eQTL |
| rs2268605 | chr11:128796335:T:C | - | 0.0359051669142757 | 0.017683462782613 | LUAD | Female-baised eQTL |
| rs7111807 | chr11:128796379:G:A | - | 0.0359051669142757 | 0.017683462782613 | LUAD | Female-baised eQTL |
| rs56145199 | chr11:128793742:T:A | - | 0.0358661539267008 | 0.0179815299635991 | LUAD | Female-baised eQTL |
| rs35594775 | chr11:128505933:T:C | - | 0.0357603942197608 | 0.0212470836980233 | LUAD | Female-baised eQTL |
| rs2268612 | chr11:128801837:A:C | - | 0.0343467951059961 | 0.0213159029635816 | LUAD | Female-baised eQTL |
| rs3758767 | chr11:128804681:C:T | - | 0.0336821396620938 | 0.0239194618475516 | LUAD | Female-baised eQTL |
| rs7126946 | chr11:128804986:C:T | - | 0.0336821396620938 | 0.0239194618475516 | LUAD | Female-baised eQTL |
| rs7113191 | chr11:128805397:T:A | - | 0.0336821396620938 | 0.0239194618475516 | LUAD | Female-baised eQTL |
| rs7127621 | chr11:128805506:C:T | - | 0.0336821396620938 | 0.0239194618475516 | LUAD | Female-baised eQTL |
| rs7113735 | chr11:128805769:T:C | - | 0.0336821396620938 | 0.0239194618475516 | LUAD | Female-baised eQTL |
| rs41302399 | chr11:128806309:T:A | - | 0.0336821396620938 | 0.0239194618475516 | LUAD | Female-baised eQTL |
| rs7936133 | chr11:128802055:C:A | - | 0.0322195843693732 | 0.0300152965398807 | LUAD | Female-baised eQTL |
| rs2268599 | chr11:128794387:G:A | - | 0.0329777626308635 | 0.0312195630159737 | LUAD | Female-baised eQTL |
| rs17128425 | chr11:124112642:T:A | - | 0.034204748522438 | 0.0348548913151286 | LUAD | Female-baised eQTL |
| rs61912960 | chr11:129265385:T:C | - | 0.0357424749451177 | 0.0368885250385863 | LUAD | Female-baised eQTL |
| rs3819826 | chr11:128780271:G:T | - | 0.0313117014359756 | 0.0392347676830551 | LUAD | Female-baised eQTL |
| rs17128423 | chr11:124112267:T:C | - | 0.0317438548830628 | 0.0395201950835161 | LUAD | Female-baised eQTL |
| rs3819825 | chr11:128780171:A:T | - | 0.0312674626966447 | 0.0400899995443596 | LUAD | Female-baised eQTL |
| rs4937409 | chr11:129286635:G:A | - | 0.0347402673513351 | 0.0429607280932457 | LUAD | Female-baised eQTL |
| rs2847376 | chr11:128781633:A:G | - | 0.0308847032118285 | 0.0450826991979837 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs2277271 | chr11:132529378:A:G | - | -0.0670564408725862 | 0.0285780273079448 | KIRC | Male-baised eQTL |
| rs7105281 | chr11:125312739:G:A | - | 0.129056938596125 | 0.0314237767907651 | KIRC | Male-baised eQTL |
| rs7112944 | chr11:131597699:G:A | - | 0.0609301010365179 | 0.0350722367152947 | KIRC | Male-baised eQTL |
| rs4076811 | chr11:131614384:A:T | - | 0.058054653324568 | 0.0439459434331713 | KIRC | Male-baised eQTL |
| rs11223641 | chr11:133950127:T:C | - | 0.057222222809635 | 0.0340583786578414 | BLCA | Male-baised eQTL |
| rs182040912 | chr11:131873625:A:G | - | 0.176016196034854 | 0.0019164095612223 | COAD | Male-baised eQTL |
| rs1790174 | chr11:132072910:T:C | - | 0.0978846306205314 | 0.0254617925610227 | COAD | Male-baised eQTL |
| rs1547897 | chr11:132076884:A:T | - | 0.0885692677050221 | 0.0352752834641143 | COAD | Male-baised eQTL |
| rs114860627 | chr11:129497992:T:C | - | -0.0678021861153609 | 0.0453405395118277 | COAD | Male-baised eQTL |
| rs3109663 | chr11:129496466:A:C | - | -0.0673974871182677 | 0.048219979006612 | COAD | Male-baised eQTL |
| rs3018432 | chr11:132082305:A:T | - | 0.0906995228504145 | 0.0486838821942858 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000043039 |
| CpG Site: cg24095303 | |
| Position to Gene: gene,enhancer | |
| Male Effect: -0.47651015035835 | |
| Female Effect: - | |
 | Gene ID: ENSG00000043039 |
| CpG Site: cg24095303 | |
| Position to Gene: gene,enhancer | |
| Male Effect: - | |
| Female Effect: -0.493563402953508 | |
 | Gene ID: ENSG00000043039 |
| CpG Site: cg16283077 | |
| Position to Gene: gene,exon,CDS | |
| Male Effect: - | |
| Female Effect: -0.493563402953508 | |
 | Gene ID: ENSG00000043039 |
| CpG Site: cg05471602 | |
| Position to Gene: gene,exon,CDS | |
| Male Effect: - | |
| Female Effect: -0.243886303382881 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg24095303 | chr11:129379525 | gene,enhancer | -0.47651015035835 | 5.36267013540706e-21 | -0.6185726092926335 | 1.3070493387750785e-22 | KIRP |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg24095303 | chr11:129379525 | gene,enhancer | -0.493563402953508 | 8.76091588907645e-114 | -0.9367777379765426 | 2.2580229917874803e-117 | LUAD |
| cg16283077 | chr11:129436835 | gene,exon,CDS | -0.493563402953508 | 8.76091588907645e-114 | -0.9367777379765426 | 2.2580229917874803e-117 | LUAD |
| cg05471602 | chr11:129436842 | gene,exon,CDS | -0.243886303382881 | 2.17441496247374e-28 | -0.6515344138510839 | 3.386456722780656e-32 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of BARX2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
